Cronos Group

Toronto, CanadaFounded 2012

Producer & Grower NASDAQ: CRON www.thecronosgroup.com

Share:X / Twitter LinkedIn Suggest a correction

About Cronos Group

Cronos Group is a Toronto-headquartered cannabis company backed by tobacco giant Altria Group, which invested CAD $2.4 billion for a 45% stake. The company focuses on innovative cannabinoid research and product development, with operations in Canada and Israel.

Key Facts

1Altria Group, maker of Marlboro cigarettes, invested CAD $2.4 billion for a 45% stake in 2019
2Invested in Ginkgo Bioworks partnership for fermentation-based cannabinoid production
3Operates through subsidiary Peace Naturals, one of the first licensed producers in Canada
4Holds strategic cannabis operations in Israel through Cronos Israel

Latest News

Cronos Group Losses Mount as Cannabis Giant Pivots Strategy

2d ago

CRON reports widening Q1 losses while implementing strategic shift, raising questions about execution in challenging cannabis market environment.

Cronos Q1 Earnings Beat Expectations on International Cannabis Surge

4d ago

CRON delivers strong first quarter results as international cannabis sales drive revenue growth and operational improvements.

Cronos Group Q1 2026 Earnings: Revenue Trends Under Microscope

8d ago

CRON reports first quarter 2026 results as cannabis sector faces margin pressure and regulatory headwinds across key markets.

Cronos Group Surges 7.7% as Cannabis Stock Shows Momentum

8d ago

CRON climbed to $2.80 on elevated volume of 1.38M shares, approaching its 52-week high amid renewed investor interest.

CRON Expands Pre-Roll Line as Cannabis Market Shifts to Value Products

11d ago

Cronos Group broadens pre-roll offerings targeting price-conscious consumers in competitive Canadian market

View all CRON news

Frequently Asked Questions

Why did Altria invest in Cronos?

Altria, the tobacco giant behind Marlboro, invested in Cronos to gain a foothold in the cannabis industry as a potential growth avenue given declining cigarette sales. The deal gave Cronos significant capital for R&D and expansion.

What is Cronos doing with biosynthesis?

Cronos partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids, aiming to produce cannabinoids more efficiently than traditional cultivation methods.